logo
Virta Health Survey Reveals Secret to Lasting Weight Loss After GLP-1s: Users Who Follow a Guided Off-ramp are 8x More Likely to Continue Losing Weight

Virta Health Survey Reveals Secret to Lasting Weight Loss After GLP-1s: Users Who Follow a Guided Off-ramp are 8x More Likely to Continue Losing Weight

Business Wire11-06-2025
DENVER--(BUSINESS WIRE)--Virta Health, a leader in diabetes reversal and sustainable weight loss with a nutrition-first approach, today released a report showing that people can maintain weight loss after stopping GLP-1 medication with the right guidance and lifestyle support—challenging the belief that weight regain is inevitable. Critically, the survey found those who tapered off GLP-1s under medical guidance were eight times more likely to continue losing weight after stopping (56%), compared to the 7% who quit abruptly.
In partnership with Wakefield Research, Virta surveyed 500 U.S. adults who previously used GLP-1s for weight loss and stopped taking them at least six months ago. While more than one in three (36%) experienced weight regain after GLP-1s, the data underscores that a structured and supported off-ramp makes the difference for sustaining long-term weight loss.
Key findings are below and detailed in the " Virta Vitals: Life After GLP-1s" corresponding report:
Guided Transitions Improve Outcomes
The survey highlights a stark difference in outcomes for people transitioning off GLP-1s with professional support compared to those who do so independently, with guidance significantly improving post-GLP-1 outcomes.
Encouragingly, nearly half (45%) of U.S. adults who stopped taking GLP-1s did so by gradually decreasing their dosage with guidance from a medical professional, while over one-third (36%) tapered off in combination with a specific lifestyle change or diet plan.
People who tapered off under medical guidance are eight times more likely to lose even more weight after stopping (56%), compared to those who quit abruptly (7%).
Even more telling: 12% of users stopped cold turkey, but among those who failed to meet their weight loss goals, that number shot up to 25%. Going it alone isn't just hard—it's risky.
Lifestyle Habits Drive Lasting Results
Among the users who stuck with their healthy diet changes after stopping GLP-1s, over half (51%) maintained their weight, and a remarkable 43% continued to lose even more weight, painting a positive picture for life post-GLP-1s.
However, a challenge remains: only 36% of users off GLP-1s for 9 to 12 months maintained their new dietary patterns. While GLP-1s can effectively jumpstart weight loss, true, sustained success hinges on integrating and maintaining these fundamental lifestyle habits.
Consumers Seek an Exit Strategy
Despite pharmaceutical companies often stating these medications constitute a lifelong commitment, user behavior suggests otherwise.
The survey revealed that only 26% of respondents used GLP-1s for 12 months or more.
This clear preference for an off-ramp underscores the need for effective strategies to help users achieve sustainable, medication-free health.
'The doomed picture of life post-GLP-1s is a myth we're actively debunking,' said Catherine Metzgar, PhD, RD, and health coach at Virta. 'Our findings show that a personalized, nutrition-first approach, coupled with a professionally guided transition plan, can set people up to not only maintain their weight loss after GLP-1 use, but actually continue their journey. Ultimately, GLP-1s can ignite a path to durable health that lasts far beyond any prescription.'
Methodology
This survey was conducted by Wakefield Research on behalf of Virta Health. Virta commissioned this research to capture the perspective of 500 nationally representative U.S. adults on their experiences with GLP-1s for weight loss. The survey was fielded between March 21 and April 1, 2025, using an email invitation and online questionnaire, with adults ages 18 and older who stopped taking GLP-1 medications a minimum of six months ago. For the interviews conducted in this particular study, the chances are 95 in 100 that a survey result does not vary, plus or minus, by more than 4.4 percentage points from the result that would be obtained if interviews had been conducted with all persons in the universe represented by the sample.
About Virta Health
Virta Health is a leader in diabetes reversal and sustainable weight loss. Through a combination of personalized nutrition, technology, and expert support, Virta empowers members to build longer, healthier lives—while reducing or eliminating the need for medications. Virta partners with the nation's largest employers, payers, and pharmacy benefit managers to improve the health of their members while reducing costs. Headquartered in Denver, Colorado, Virta's mission is to reverse diabetes and obesity in one billion people. For more information, visit www.virtahealth.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Lanier Law Firm Representing Health Choice Alliance in Litigation Alleging Eli Lilly Offered Kickbacks to Texas Health Care Providers
Lanier Law Firm Representing Health Choice Alliance in Litigation Alleging Eli Lilly Offered Kickbacks to Texas Health Care Providers

Business Wire

time39 minutes ago

  • Business Wire

Lanier Law Firm Representing Health Choice Alliance in Litigation Alleging Eli Lilly Offered Kickbacks to Texas Health Care Providers

MARSHALL, Texas--(BUSINESS WIRE)--Texas Attorney General Ken Paxton has filed a lawsuit in state court against Eli Lilly and Co., accusing the pharmaceutical giant of bribing and inducing medical providers to prescribe its most profitable drugs. In return, physicians were offered unlawful payments and a range of free services in violation of state law. 'This scheme corrupted medical decision-making by giving doctors quid pro quo services obviously intended to influence prescribing,' says Mark Lanier of The Lanier Law Firm. Texas is intervening in the litigation as a plaintiff with the Health Choice Alliance, a research organization jointly represented by The Lanier Law Firm and McKool Smith PC. The lawsuit, filed in Harrison County, accuses Eli Lilly of offering the kickbacks to steer providers to write prescriptions for as many as 14 high-demand drugs such as the GLP-1 medications Mounjaro and Zepbound, resulting in millions of dollars in claims to the state's Medicaid program. Because those charges resulted from Eli Lilly's suspect marketing and service arrangements, the lawsuit claims the practice violated the Texas Health Care Program Fraud Prevention Act and Texas Anti-Kickback Statute. 'This scheme corrupted medical decision-making by giving doctors quid pro quo services obviously intended to influence prescribing,' says Mark Lanier of The Lanier Law Firm. 'As a result, Texas Medicaid became responsible for millions of dollars in improper payments. This case should serve as a warning to the other pharmaceutical giants that such unlawful activities will be investigated and prosecuted.' The lawsuit states that the company provided free nursing services to patients who were prescribed Eli Lilly drugs and offered a supposedly independent web-based service that was in fact managed by Eli Lilly to direct patients to the desired drugs. In addition, the kickbacks involved free services to physicians to obtain insurance authorizations and authorization from Texas Medicaid on behalf of patients, a time-consuming process with administrative costs that are not normally reimbursable to the provider. 'Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme,' said Attorney General Paxton in announcing the lawsuit. 'Eli Lilly fraudulently sought to maximize profits at taxpayer expense and put corporate greed over people's health. I will not stand by while corporations unlawfully manipulate our healthcare system to line their own pockets.' The case is Texas vs. Eli Lilly & Co Inc., filed in the 71st District Court of Harrison County, Texas. About The Lanier Law Firm For more than 30 years, the men and women at The Lanier Law Firm have worked tirelessly, throughout the United States, to find unique and effective solutions for their clients. More than 50 skilled attorneys practice law in a broad array of areas, including business litigation, pharmaceutical litigation, asbestos exposure, oil and gas litigation, personal injury as well as defective and dangerous products, among others. Named an Elite Trial Law Firm by The National Law Journal, The Lanier Law Firm has offices in Houston, New York, and Los Angeles.

CILA Therapeutics Awarded NCATS Grant to Advance a Transformational Platform That Significantly Enhances Inhaled Delivery of RNA-LNP Into Lung Cells
CILA Therapeutics Awarded NCATS Grant to Advance a Transformational Platform That Significantly Enhances Inhaled Delivery of RNA-LNP Into Lung Cells

Business Wire

timean hour ago

  • Business Wire

CILA Therapeutics Awarded NCATS Grant to Advance a Transformational Platform That Significantly Enhances Inhaled Delivery of RNA-LNP Into Lung Cells

BOSTON--(BUSINESS WIRE)-- CILA Therapeutics has been awarded a competitive grant from the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to advance the development of its proprietary CIL-Key™ platform — a novel, gene-agnostic delivery technology that significantly and reproducibly enhances the transfection efficiency and delivery of inhaled RNA-loaded lipid nanoparticles (RNA-LNPs) into lung epithelial cells. 'This milestone provides strong validation of CILA's scientific approach and vision to deliver practical, scalable and patient-centric solutions for some of the most formidable challenges in pulmonary medicine," said Safia Rizvi, CEO, CILA Therapeutics Share In preclinical studies, the CIL-Key™ platform (also referred to as CIL-0X in the grant) achieved up to a 430% increase in delivery of functionally intact RNA into human bronchial epithelial cells cultured at an air-liquid interface (ALI), demonstrating utility across multiple RNA-LNP formulations. 'This milestone provides strong validation of CILA's scientific approach and vision to deliver practical, scalable and patient-centric solutions for some of the most formidable challenges in pulmonary medicine,' said Safia Rizvi, CEO of CILA Therapeutics. CIL-Key™ is designed to enable efficient, localized intracellular delivery of RNA-based modalities while minimizing systemic exposure. The platform could offer significant advantages for companies developing inhaled RNA therapies and vaccines for a broad range of lung diseases, including Primary Ciliary Dyskinesia (PCD), Cystic Fibrosis (CF), COPD and Pulmonary Fibrosis, as well as respiratory infections including influenza, RSV and COVID-19. Chronic pulmonary diseases affect more than 34 million people in the U.S. and more than 545 million globally. These often progressive, life-limiting conditions have a significant impact on quality of life and a high economic burden, creating an urgent demand for novel, effective and easy-to-administer treatments like those powered by CIL-Key™. About CILA Therapeutics CILA Therapeutics is a biotechnology company focused on improving lung health through transformative, scalable, accessible therapies and technologies that easily integrate into patients' daily lives. Its vision is to empower people with pulmonary diseases to breathe easily and live fully. CILA's pipeline includes first-in-class inhaled therapeutics and CIL-Key™, a proprietary platform to enhance delivery of RNA-based therapeutics and vaccines targeting a wide spectrum of pulmonary diseases. Visit CILA is actively seeking strategic partnerships to expand the platform's application across diverse RNA-based pipelines for rare and common pulmonary indications.

RAM Technologies' Rapid Growth Earns National Recognition on Inc. 5000 List
RAM Technologies' Rapid Growth Earns National Recognition on Inc. 5000 List

Yahoo

timean hour ago

  • Yahoo

RAM Technologies' Rapid Growth Earns National Recognition on Inc. 5000 List

PHILADELPHIA, August 14, 2025--(BUSINESS WIRE)--RAM Technologies, Inc., a leading technology enabled services provider to Medicare Advantage, Special Needs and Managed Medicaid health plans, has earned a place on the 2025 Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America. With three-year revenue growth of nearly 100%, this marks the company's ninth time on the list. The Inc. 5000 offers a data-driven look at the nation's most successful companies within the economy's most dynamic segment—independent, entrepreneurial businesses. Rankings are based on percentage revenue growth from 2021 to 2024, and RAM Technologies was honored for its exceptional growth and innovation. "It's an honor to once again be recognized on the Inc. 5000 list," said Robert Tulio, CEO of RAM Technologies. "Our growth is the result of a clear mission to equip government-sponsored health plans with software and services to operate efficiently and put members at the center of every decision. This achievement reflects the impact we're making in the healthcare industry, and our team's focus on innovation and quality." The company's sustained growth has been fueled by expanding relationships with health plans nationwide, a commitment to exceptional client service and the ability to provide BPaaS solutions that enhance outcomes for clients. RAM Technologies specializes in delivering purpose-built solutions for government-sponsored health plans. The company's core platform, HEALTHsuite Advantage, gives health plans added flexibility through the choice of SaaS and BPaaS deployment models. By combining software with expert implementation and support, RAM helps health plans reduce costs, streamline operations and improve member experiences. "Our solutions give health plans tools to operate more efficiently, deliver a better experience for members and ensure compliance with regulatory requirements," said Tulio. "We're proud to have achieved sustained growth in such a competitive market, and we remain focused on delivering solutions to help our clients succeed." For the full list, company profiles, and a searchable database by industry and location, visit: About RAM Technologies RAM Technologies is a leading provider of enterprise solutions for government-sponsored healthcare payers. For over 44 years RAM Technologies has led the way in the creation of comprehensive, end-to-end SaaS and BPaaS solutions for health plans administering Medicare Advantage, Managed Medicaid and Special Needs plans. Our deep understanding of Medicare and Medicaid guarantees seamless integration and operational ease, allowing health plan staff to focus on what matters most. To learn more about RAM Technologies visit View source version on Contacts Media Contact Robert Meyer, RAM Technologies, Inc., rmeyer@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store